Global Cases of Parkinson's Disease Projected to Reach 3.15 Million by 2033: Report

New Delhi: Parkinson’s disease is projected to affect 3.15 million individuals worldwide by 2033, an increase from 2.64 million cases in 2023, reflecting an annual growth rate of 1.94 percent, according to a report released on Monday. The findings, published by GlobalData, a leading data and analytics firm, highlight a significant rise in the prevalence of this progressive brain disorder in the coming decade, especially in seven major countries.

The report reveals that the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan will experience a notable increase in diagnosed cases. Among these nations, the United States is forecasted to have the highest number of diagnosed prevalent cases, reaching 1.24 million by 2033. In contrast, Italy is expected to have the lowest number, with nearly 0.16 million cases.

According to Rahul N Ravi, Senior Epidemiologist at GlobalData, “In 2023, adults aged 60 and older accounted for over 90 percent of diagnosed prevalent cases of Parkinson’s disease, while individuals aged 18 to 39 comprised less than 1 percent. This age distribution reflects the well-documented association between Parkinson’s disease and older populations.”

He further noted, “There is a slight predominance of diagnosed cases among men compared to women. These differences in prevalence across genders and markets may be attributed to variations in demographic structures and significant differences in sex-specific prevalence rates.”

Parkinson’s disease, an incurable neurodegenerative disorder, is clinically classified as a movement disorder characterized by prominent motor symptoms such as tremors, rigidity, and bradykinesia. It is the second most common chronic, progressive neurodegenerative condition among elderly populations, following Alzheimer’s disease. Although current treatments can alleviate symptoms, no cure exists to halt or slow the disease's progression.

The report also underscores the challenges posed by ageing populations in addressing Parkinson’s disease. Ravi emphasized, “Parkinson’s disease is among the most common chronic, progressive neurodegenerative disorders impacting the elderly. Countries experiencing a rise in ageing populations must implement strategies to meet the healthcare needs of individuals affected by Parkinson’s disease.”

In the next decade, these seven countries are expected to play a pivotal role in advancing Parkinson’s disease treatments and healthcare planning, given their significant demographic shifts.

As per IANS, the findings highlight an urgent need for increased research and healthcare strategies to address this growing public health concern globally. Developing effective policies and support systems for elderly populations will be crucial in mitigating the burden of Parkinson’s disease.